711-1012

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
711 (USA) · Dr. Jansen
consented 2013-04-03

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-16 (study day 14.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-16 (study day 14.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-16 (study day 14.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-16 (study day 14.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE PRURITUS — outcome: RECOVERED/RESOLVED; onset 2013-04-16 (study day 14.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE URTICARIA — outcome: RECOVERED/RESOLVED; onset 2013-04-29 (study day 27.0); relationship: PROBABLE

moderate assessed

Moderate NASOPHARYNGITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-27 (study day 25.0); relationship: NONE

Data queries

No data queries.